Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy, safety and tolerability of 3% LTX-109 for nasal decolonisation of Staphylococcus aureus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Staphylococcus Aureus Nasal Colonization

Drugs mentioned

• LTX-109 (3%) (LTX-109)

Snippet

Sponsor: Pharma Holdings AS | Conditions: Nasal Decolonization of Staphylococcus Aureus | Phase 2 | Status: COMPLETED